logo

Jazz Pharmaceuticals Plc (JAZZ)



Trade JAZZ now with
  Date
  Headline
7/22/2020 7:33:38 AM Jazz Pharma: FDA Approves Xywav Oral Solution For Cataplexy Or Excessive Daytime Sleepiness Associated With Narcolepsy
6/9/2020 7:02:25 AM Jazz Pharmaceuticals Prices Private Offering Of $850 Mln Of 2.000% Exchangeable Senior Notes Due 2026
6/8/2020 7:05:37 AM Jazz Pharma Announces Private Offering Of $850 Mln Of Exchangeable Senior Notes Due 2026
5/11/2020 8:36:12 AM Bionical Emas, Jazz Pharma Agree For Expanded Access To Lurbinectedin In United States
2/17/2020 2:33:42 AM PharmaMar And Jazz Pharma Announce FDA Acceptance And Priority Review Of NDA For Lurbinectedin
1/22/2020 8:11:10 AM Jazz Submits NDA For JZP-258 For Cataplexy And Excessive Daytime Sleepiness Associated With Narcolepsy
1/22/2020 2:40:10 AM PharmaMar, Jazz U.S. License Agreement For Lurbinectedin Effective With Expiration Of HSR Waiting Period
1/20/2020 11:25:20 AM Jazz Pharma Gets EU Marketing Approval For Sunosi For Excessive Daytime Sleepiness In Adults With Narcolepsy
12/30/2019 8:07:33 AM Jazz:First Patient Enrolled In Pivotal Phase 2/3 Study Evaluating JZP-458 For Treatment Of Acute Lymphoblastic Leukemia
12/19/2019 8:02:26 AM PharmaMar And Jazz Sign License Agreement For Lurbinectedin In U.S.; Jazz To Pay Upfront Payment Of $200 Mln
11/15/2019 6:46:32 AM Jazz Pharma Receives Positive CHMP Opinion For Solriamfetol